Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2018 / N 3

Принципы адекватного выполнения ингаляции
В.В. Архипов, Н.Б. Лазарева

References
1. Price D, David-Wang A, Cho SH, Ho JC, Jeong JW, Liam CK, Lin J, Muttalif AR, Perng DW, Tan TL, Yunus F, Neira G. Time for a new language for asthma control: results from REALISE Asia. Journal of Asthma and Allergy 2015 Sep;8:93-103.
2. Sanchis J, Gich I, Pedersen S; Aerosol Drug Management Improvement Team (ADMIT). Systematic review of errors in inhaler use: has patient technique improved over time? Chest 2016 Aug;150(2):394-406.
3. Plaza V, Sanchis J. Medical personnel and patient skill in the use of metered dose inhalers: a multicentric study. CESEA Group. Respiration 1998;65(3):195-8.
4. Crompton GK, Barnes PJ, Broeders M, Corrigan C, Corbetta L, Dekhuijzen R, Dubus JC, Magnan A, Massone F, Sanchis J, Viejo JL, Voshaar T; Aerosol Drug Management Improvement Team. The need to improve inhalation technique in Europe: a report from the Aerosol Drug Management Improvement Team. Respiratory Medicine 2006 Sep;100(9):1479-94.
5. Roggeri A, Micheletto C, Roggeri DP. Inhalation errors due to device switch in patients with chronic obstructive pulmonary disease and asthma: critical health and economic issues. International Journal of Chronic Obstructive Pulmonary Disease 2016 Mar;11:597-602.
6. Plaza V, Sanchis J, Roura P, Molina J, Calle M, Quirce S, Viejo JL, Caballero F, Murio C. Physicians’ knowledge of inhaler devices and inhalation techniques remains poor in Spain. Journal of Aerosol Medicine and Pulmonary Drug Delivery 2012 Feb;25(1):16-22.
7. Takaku Y, Kurashima K, Ohta C, Ishiguro T, Kagiyama N, Yanagisawa T, Takayanagi N. How many instructions are required to correct inhalation errors in patients with asthma and chronic obstructive pulmonary disease. Respiratory Medicine 2017 Feb;123:110-5.
8. Molimard M, Raherison C, Lignot S, Depont F, Abouelfath A, Moore N. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. Journal of Aerosol Medicine 2003 Fall;16(3):249-54.
9. van der Palen J, Thomas M, Chrystyn H, Sharma RK, van der Valk PD, Goosens M, Wilkinson T, Stonham C, Chauhan AJ, Imber V, Zhu CQ, Svedsater H, Barnes NC. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices. NPJ Primary Care Respiratory Medicine 2016 Nov;26:16079.
10. Rootmensen GN, van Keimpema AR, Jansen HM, de Haan RJ. Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped scoring method. Journal of Aerosol Medicine and Pulmonary Drug Delivery 2010 Oct;23(5):323-8.
11. Dal Negro RW, Longo P, Ziani OV, Bonadiman L, Turco P. Instant velocity and consistency of emitted cloud change by the different levels of canister filling with Metered Dose Inhalers (MDIs), but not with Soft Mist Inhalers (SMIs): a bench study. Multidisciplinary Respiratory Medicine 2017;12:13.
12. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. The European Respiratory Journal 1998 Dec;12(6):1346-53.
13. Pitcairn G, Reader S, Pavia D, Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. Journal of Aerosol Medicine 2005 Fall;18(3):264-72.
14. DelGaudio JM. Steroid inhaler laryngitis: dysphonia caused by inhaled fluticasone therapy. Archives of Otolaryngology–Head & Neck Surgery 2002 Jun;128(6):677-81.
15. Brand P, Meyer T, Weuthen T, Timmer W, Berkel E, Wallenstein G, Scheuch G. Lung deposition of radiolabeled tiotropium in healthy subjects and patients with chronic obstructive pulmonary disease. Journal of Clinical Pharmacology 2007 Oct;47(10):1335-41.
16. Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. American Journal of Respiratory and Critical Care Medicine 2005 Dec;172(12):1497-504.
17. Bisgaard H, O’Callaghan C, Smaldone GC. Drug delivery to the lung. (Lung Biology in Health and Disease. Volume 162.) New York, NY: CRC Press; 2001. 536 p.
18. Zanen P, Go LT, Lammers JW. Optimal particle size for beta2-agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax 1996 Oct;51(10):977-80.
19. Macklem PT. The physiology of small airways. American Journal of Respiratory and Critical Care Medicine 1998 May;157(5 Pt 2):S181-3.
20. Dolovich M. New delivery systems and propellants. Canadian Respiratory Journal 1999 May-Jun;6(3):290-5.
21. Newman SP. Principles of metered-dose inhaler design. Respiratory Care 2005 Sep;50(9):1177-90.
22. Smyth HD. The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. Advanced Drug Delivery Reviews 2003 Jul;55(7):807-28.
23. Newman SP, Weisz AW, Talaee N, Clarke SW. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax 1991 Oct;46(10):712-6.
24. Price DB, Román-Rodríguez M, McQueen RB, Bosnic-Anticevich S, Carter V, Gruffydd-Jones K, Haughney J, Henrichsen S, Hutton C, Infantino A, Lavorini F, Law LM, Lisspers K, Papi A, Ryan D, Ställberg B, van der Molen T, Chrystyn H. Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes. The Journal of Allergy and Clinical Immunology: in Practice 2017 Jul-Aug;5(4):1071-81.e9.
25. Laube BL, Janssens HM, de Jongh FH, Devadason SG, Dhand R, Diot P, Everard ML, Horvath I, Navalesi P, Voshaar T, Chrystyn H; European Respiratory Society; International Society for Aerosols in Medicine. What the pulmonary specialist should know about the new inhalation therapies. The European Respiratory Journal 2011 Jun;37(6):1308-31.
26. Kafaei Shirmanesh Y, Jones MD. Physical ability of people with rheumatoid arthritis and age-sex matched controls to use four commonly prescribed inhaler devices. Respiratory Medicine 2018 Feb;135:12-4.
27. Hanania NA, Braman S, Adams SG, Adewuya R, Ari A, Brooks J, Mahler DA, Ohar JA, Peters J, Sanjar S. The role of inhalation delivery devices in COPD: perspectives of patients and health care providers. Chronic Obstructive Pulmonary Diseases (Miami, Fla.) 2018 Apr;5(2):111-23.
28. Hatley RH, Parker J, Pritchard JN, von Hollen D. Variability in delivered dose from pressurized metered-dose inhaler formulations due to a delay between shake and fire. Journal of Aerosol Medicine and Pulmonary Drug Delivery 2017 Feb;30(1):71-9.
29. Lavorini F, Pistolesi M, Usmani OS. Recent advances in capsule-based dry powder inhaler technology. Multidisciplinary Respiratory Medicine 2017 May;12:19.
30. Hoppentocht M, Hagedoorn P, Frijlink HW, de Boer AH. Technological and practical challenges of dry powder inhalers and formulations. Advanced Drug Delivery Reviews 2014 Aug;75:18-31.
31. Azouz W, Chrystyn H. Clarifying the dilemmas about inhalation techniques for dry powder inhalers: integrating science with clinical practice. Primary Care Respiratory Journal 2012 Jun;21(2):208-13.
32. Demoly P, Hagedoorn P, de Boer AH, Frijlink HW. The clinical relevance of dry powder inhaler performance for drug delivery. Respiratory Medicine 2014 Aug;108(8):1195-203.
33. Hira D, Koide H, Nakamura S, Okada T, Ishizeki K, Yamaguchi M, Koshiyama S, Oguma T, Ito K, Funayama S, Komase Y, Morita SY, Nishiguchi K, Nakano Y, Terada T. Assessment of inhalation flow patterns of soft mist inhaler co-prescribed with dry powder inhaler using inspiratory flow meter for multi inhalation devices. PLoS One 2018 Feb;13(2):e0193082.
34. Nielsen KG, Skov M, Klug B, Ifversen M, Bisgaard H. Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizer. The European Respiratory Journal 1997 Sep;10(9):2105-9.
35. Pavkov R, Mueller S, Fiebich K, Singh D, Stowasser F, Pignatelli G, Walter B, Ziegler D, Dalvi M, Dederichs J, Rietveld I. Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Current Medical Research and Opinion 2010 Nov;26(11):2527-33.
36. Magnussen H, Watz H, Zimmermann I, Macht S, Greguletz R, Falques M, Jarreta D, Garcia Gil E. Peak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPD. Respiratory Medicine 2009 Dec;103(12):1832-7.
37. Corradi M, Chrystyn H, Cosio BG, Pirozynski M, Loukides S, Louis R, Spinola M, Usmani OS. NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma. Expert Opinion on Drug Delivery 2014 Sep;11(9):1497-506.
38. Yang TT, Li S, Wyka B, Kenyon D. Drug delivery performance of the mometasone furoate dry powder inhaler. Journal of Aerosol Medicine 2001 Winter;14(4):487-94.
39. Pedersen S, Hansen OR, Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Archives of Disease in Childhood 1990 Mar;65(3):308-10.
40. Ghosh S, Ohar JA, Drummond MB. Peak inspiratory flow rate in chronic obstructive pulmonary disease: implications for dry powder inhalers. Journal of Aerosol Medicine and Pulmonary Drug Delivery 2017 Dec;30(6):381-7.
41. Grant AC, Walker R, Hamilton M, Garrill K. The ELLIPTA® dry powder inhaler: design, functionality, in vitro dosing performance and critical task compliance by patients and caregivers. Journal of Aerosol Medicine and Pulmonary Drug Delivery 2015 Dec;28(6):474-85.
42. van der Palen J. Peak inspiratory flow through diskus and turbuhaler, measured by means of a peak inspiratory flow meter (In-Check DIAL). Respiratory Medicine 2003 Mar;97(3):285-9.
43. Chodosh S, Flanders JS, Kesten S, Serby CW, Hochrainer D, Witek TJ. Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. Journal of Aerosol Medicine 2001 Fall;14(3):309-15.
44. Laube BL, Norman PS, Adams GK 3rd. The effect of aerosol distribution on airway responsiveness to inhaled methacholine in patients with asthma. Journal of Allergy and Clinical Immunology 1992 Feb;89(2):510-8.
45. Chrystyn H, Safioti G, Keegstra JR, Gopalan G. Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: an in vitro comparison of Spiromax with Turbuhaler. International Journal of Pharmaceutics 2015 Aug;491(1-2):268-76.
46. Sanders MJ. Guiding inspiratory flow: development of the in-check DIAL G16, a tool for improving inhaler technique. Pulmonary Medicine 2017 Nov;2017:1495867.
47. Sulaiman I, Cushen B, Greene G, Seheult J, Seow D, Rawat F, MacHale E, Mokoka M, Moran CN, Sartini Bhreathnach A, MacHale P, Tappuni S, Deering B, Jackson M, McCarthy H, Mellon L, Doyle F, Boland F, Reilly RB, Costello RW. Objective assessment of adherence to inhalers by patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2017 May;195(10):1333-43.
48. Horváth A, Balásházy I, Tomisa G, Farkas Á. Significance of breath-hold time in dry powder aerosol drug therapy of COPD patients. European Journal of Pharmaceutical Sciences 2017 Jun;104:145-9.
49. Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P, Serra M, Scichilone N, Sestini P, Aliani M, Neri M; Gruppo Educazionale Associazione Italiana Pneumologi Ospedalieri. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respiratory Medicine 2011 Jun;105(6):930-8.
50. Frijlink HW, De Boer AH. Dry powder inhalers for pulmonary drug delivery. Expert Opinion on Drug Delivery 2004 Nov;1(1):67-86.
51. Chapman KR, Fogarty CM, Peckitt C, Lassen C, Jadayel D, Dederichs J, Dalvi M, Kramer B. Delivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPD. International Journal of Chronic Obstructive Pulmonary Disease 2011;6:353-63.
52. Azouz W, Chetcuti P, Hosker HS, Saralaya D, Stephenson J, Chrystyn H. The inhalation characteristics of patients when they use different dry powder inhalers. Journal of Aerosol Medicine and Pulmonary Drug Delivery 2015 Feb;28(1):35-42.
53. Perriello EA, Sobieraj DM. The Respimat Soft Mist inhaler, a novel inhaled drug delivery device. Connecticut Medicine 2016 Jun-Jul;80(6):359-64.
54. Hochrainer D, Hölz H, Kreher C, Scaffidi L, Spallek M, Wachtel H. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. Journal of Aerosol Medicine 2005 Fall;18(3):273-82.
55. Criée CP, Meyer T, Petro W, Sommerer K, Zeising P. In vitro comparison of two delivery devices for administering formoterol: Foradil P and Formoterol-ratiopharm single-dose capsule inhaler. Journal of Aerosol Medicine 2006 Winter;19(4):466-72.
56. Ciciliani A, Wachtel H, Heussel C, Langguth P. Evaluation of Respimat® Soft Mist™ inhaler based on in vitro measurements and CFD simulations. Respiratory Drug Delivery 2015;2(2015):357-62.
57. Ciciliani A, Wachtel H, Langguth P. Comparing Respimat® Soft Mist™ inhaler and DPI aerosol deposition by combined in vitro measurements and CFD simulations. Respiratory Drug Delivery 2014;2(2014):453-6.
58. Erdélyi T, Lázár X, Odler B, Bohács A, Eszes N, Jókay Á, Farkas A, Balásházy I, Müller V. Reproducibility of inhaler use and pulmonary drug deposition in COPD. European Respiratory Journal 2016;48:PA960.
59. Barczok M, Perleberg C, Kardos P, Hodder R. Presented at VIII Deutsches Aerosol Therapie Seminar, 2003 Nov; Marburg, Germany.
  

[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]